Merck, Protiva make nice

Seemingly spending more time in court rooms than laboratories, Protiva Biotherapeutics
| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
VANCOUVER—Seemingly spending more time in court rooms than laboratories, Protiva Biotherapeutics announced it has granted Merck a non-exclusive license to its stable nucleic acid-lipid particles (SNALP) platform for ongoing RNAi research and development, bringing to an end the Canadian company's wrangling with Merck subsidiary Sirna Therapeutics. While financial details were not disclosed, Protiva will receive a one-time payment from Merck as well as milestone and royalty payments on any product candidates that may develop.
 
"Merck's licensing of our 'SNALP' technology is an important validation of the skill of our scientific team and our leadership position in the siRNA delivery space," says Dr. Mark Murray, Protiva president and CEO. "Protiva is moving forward with financial strength and a continued focus on the development of new therapeutic products and business alliances."
 
In April, Protiva had secured a preliminary injunction in the California Superior Court prohibiting Sirna from using Protiva's technology in its RNAi discovery efforts. Practically thoughout 2006, Protiva spent time in the same court battling Inex Pharmaceuticals for what Protiva saw as the unlawful spin-out of its technology into Tekmira Pharmaceuticals, an Inex spin-off. Protiva dismissed that case, without prejudice, in December 2006 to pursue the Sirna case.

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Surface rendering of two interacting proteins (green and peach) bound together by a small molecule ligand at their interface, illustrating a protein-ligand binding event.
Learn how molecular dynamics, AI-aided design, and structural insights combine to reshape how therapeutic proteins are created, validated, and optimized.
Stem cells are shown as clear, purple, and blue spheres against a dark blue and black background.
Human-relevant, ready-to-use stem cell models are reshaping drug discovery, toxicity testing, and personalized medicine.
Characterizing lipid nanoparticles for RNA therapeutic development
Integrated multiomics and advanced nanoparticle analytics are improving how researchers perform RNA delivery, increasing therapeutic success.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue